Legal · FL
Florida Sues Insulin Manufacturers and PBMs Over Alleged Price Inflation Scheme
Florida Attorney General James Uthmeier filed suit in Miami-Dade County Circuit Court against Eli Lilly, Novo Nordisk, Sanofi, and three pharmacy benefit managers, alleging they inflated insulin list prices and paid rebates that increased costs for consumers. The lawsuit accuses the companies of a coordinated pricing scheme involving diabetes medications. The action reflects growing state enforcement efforts targeting pharmaceutical pricing practices that affect state Medicaid pharmacy expenditures and beneficiary access to essential medications. The complaint follows similar insulin pricing litigation in other states.
Why it mattersState litigation against insulin manufacturers and PBMs could affect Medicaid pharmacy benefit design, rebate arrangements, and drug pricing strategies, with potential implications for state budgets and beneficiary cost-sharing in Medicaid programs.